Is Omkar Pharmachem overvalued or undervalued?

As of 12 August 2025, the valuation grade for Omkar Pharmachem has moved from risky to very expensive, indicating a significant shift in its perceived value. The company is currently considered overvalued. Key ratios include a PE ratio of 25.90, an EV to EBIT ratio of 26.13, and a ROCE of only 3.17%, which raises concerns about its profitability relative to its valuation. In comparison to its peers, Omkar Pharmachem's valuation metrics appear less favorable. For instance, Sun Pharma has a PE ratio of 33.93, while Cipla offers a more attractive PE of 22.77. Additionally, the PEG ratio of 4.92 suggests that the company's growth prospects may not justify its current price. Despite a strong historical performance over the last decade, with a return of 323.06%, the current valuation does not align with its financial fundamentals, reinforcing the conclusion that Omkar Pharmachem is overvalued.